407-22-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-6-methylpyridine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds, including:
1. 2-fluoro-6-pyridinecarboxylic acid, which may have potential applications in the development of new drugs targeting specific receptors or enzymes.
2. 2,2′-[1-(6-methylpyridin-2-yl)ethane-1,1-diyl]dipyridine, which could be utilized in the creation of novel molecules with potential therapeutic properties.
3. 2-fluoropyridine-6-aldoxime, a compound that may be further modified for use in medicinal chemistry.
4. 2-fluoro-6-(dibromomethyl)pyridine, which can be a starting point for the development of new chemical entities with specific biological activities.
The versatility of 2-fluoro-6-methylpyridine as a chemical intermediate makes it a valuable compound in the pharmaceutical industry for the development of new drugs and therapeutic agents.

InChI:InChI=1/C4H4F5I/c5-3(6,1-2-10)4(7,8)9/h1-2H2

Upstream product

• 1824-81-3 2-Amino-6-methylpyridine 
• 18368-63-3 6-chloro-2-picoline 

Downstream Products

• 402-69-7 6-fluoropyridine-2-carboxylic acid 
• 3279-76-3 6-methyl-2(1H)-pyridone 
• 162854-31-1 6-fluoro-2-pyridinepropanol 
• 208110-81-0 2-Fluoropyridine-6-carboxaldehyde 
• 878744-13-9 2-methyl-2-(6-methylpyridin-2-yl)propanenitrile 
• 315180-16-6 6-(chloromethyl)-2-fluoropyridine 
• 1056598-94-7 2-(chloromethyl)-6-fluoropyridine hydrochloride 
• 1088991-72-3 2-methyl-6-(((3R,6R)-6-methyl-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)piperidin-3-yl)methoxy)pyridine 
• 100202-78-6 6-(bromomethyl)-2-fluoropyridine 
• 1243694-61-2 2-fluoro-6-(dibromomethyl)pyridine 
• 64197-03-1 6-fluoropyridine-2-carbonyl chloride 
• 205744-18-9 (6-fluoropyridine-2-yl)methylamine 
• 63071-03-4 2-methoxy-6-methyl-pyridine 

Relevant academic research and scientific papers

Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18

With the aim to develop a specific radioligand for imaging the cyclic nucleotide phosphodiesterase 5 (PDE5) in brain by positron emission tomography (PET), seven new fluorinated inhibitors (3–9) were synthesized on the basis of a quinoline core. The inhibitory activity for PDE5 together with a panel of other PDEs was determined in vitro and two derivatives were selected for IC50 value determination. The most promising compound 7 (IC50 = 5.92 nM for PDE5A), containing a 3-fluoroazetidine moiety, was further radiolabeled by aliphatic nucleophilic substitution of two different leaving groups (nosylate and tosylate) using [18F]fluoride. The use of the nosylate precursor and tetra-n-butyl ammonium [18F]fluoride ([18F]TBAF) in 3-methyl-3-pentanol combined with the addition of a small amount of water proved to be the best radiolabeling conditions achieving a RCY of 4.9 ± 1.5% in an automated procedure. Preliminary biological investigations in vitro and in vivo were performed to characterize this new PDE5 radioligand. Metabolism studies of [18F]7 in mice revealed a fast metabolic degradation with the formation of radiometabolites which have been detected in the brain.

Synthesis of some fluorine-containing pyridinealdoximes of potential use for the treatment of organophosphorus nerve-agent poisoning

Fluoroheterocyclic aldoximes were screened as therapeutic agents for the treatment of anticholinesterase poisoning. 2-Fluoropyridine-3- and -6-aldoxime, and 3-fluoropyridine-2- and -4-aldoxime, were synthesised. Attempts to obtain 3,5,6-trifluoropyridine-2,4-bis(aldoxime) and -2-aldoxime, however, proved unsuccessful. Pentafluorobenzaldoxime was prepared by oximation of pentafluorobenzaldehyde. Acid dissociation constants (pKa) and second-order rate constants (kox-) of the fluorinated pyridinealdoximes towards sarin were measured. 2,3,5,6-Tetrafluoropyridine-4- aldoxime had the best profile: its kox- approached that of the therapeutic oxime P2S (310 vs. 120 l mol-1 min-1), but its higher pKa (9.1 vs. 7.8) fell short of the target figure of 8 required for reactivation of inhibited acetylcholinesterase in vivo. N-alkylation of the fluorinated pyridine-aldoximes may reduce their pK a nearer to 8 and enhance their therapeutic potential. Crown Copyright

Facile preparation of aromatic fluorides by deaminative fluorination of aminoarenes using hydrogen fluoride combined with bases

One-pot deaminative fluorination of aminoarenes including heteroaromatics, namely, diazotization of aminoarenes followed by in situ fluoro-dediazoniation of the corresponding diazonium ions, was successfully accomplished to produce fluoroarenes in high yields by using hydrogen fluoride combined with base solutions. The diazotization stage has been found to play the most important part in yielding fluoroarenes effectively. It was greatly influenced by the composition of the HF solution and enhanced by employing appropriate amounts of bases such as pyridine under carefully controlled conditions. The fluoro-dediazoniation stage was effectively accelerated photochemically to afford fluoroarenes having polar substituents such as hydroxyl, nitro and so on in high yields.

NUCLEOPHILIC FLUORINATION OF CHLORINATED N-HETEROCYCLES WITH TETRABUTYLPHOSPHONIUM HYDROGENDIFLUORIDE AND DIHYDROGENTRIFLUORIDE

Fluorination of various chlorinated N-heterocycles with tetrabutylphosphonium hydrogendifluoride (1) or dihydrogentrifluoride (2) readilly proceeded in high yields under mild conditions.

A Facile Preparation of Fluoropyridines from Aminopyridines via Diazotation and Fluorodediazoniation in HF or HF-Pyridine Solutions

Fluoropyridines were prepared in high yields by dizotation of aminopyridines in HF or HF-pyridine solutions, followed by dediazoniation in situ at 20-60 deg C.